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clinical and demographic differences between patients,
and to better understand deﬁnitively the value of new
treatments.
PCN24
DEVELOPMENT OF A PREFERENCE
ELICITATION INSTRUMENT FOR USE IN
PATIENTS WITH NEWLY DIAGNOSED BRAIN
METASTASES IN A PROSPECTIVE RANDOMIZED
CLINICAL TRIAL
Adamus AT, Chang EL, Arbuckle R, King K
The University of Texas M.D. Anderson Cancer Center,
Houston,TX, USA
OBJECTIVE: The prevalence of brain metastases in
cancer patients is 20–40% and treatment options offer
median survivals of 4–10 months. Comparing two treat-
ments that do not offer increases in survival in a disease
state with a small survival rate lends itself to the study of
patient preferences. Patients are left to choose between
the risk of recurrent metastatic disease or the physical 
and cognitive side effects associated with treatment. The
objective of this study was to assess the feasibility of the
time trade-off method in patients with brain metastases
participating in a clinical trial. METHODS: An instru-
ment was developed for patients with brain metastases
undergoing radiosurgery with and without whole brain
radiation. Research nurses were trained to administer the
instrument face-to-face during clinic visits. RESULTS:
The instrument included a written script, data collection
form, and visual aid to facilitate the understanding of
trading time. Patients traded time for 3 different time
periods—10 years, 5 years, and one year. The piloted
instrument resulted in two changes: 1) the visual aid was
eliminated because it did not add to patients understand-
ing of trading time, and 2) the concept of “optimal
health” was used instead of “perfect health” because
patients had difﬁculty with the term. Currently, the
instrument has been administered to 25 patients. Fifty-six
percent, 44%, and 36% of patients traded time in the 10-
year, 5-year, and 1-year time period respectively. Three
patients from each time period increased the time that
they would trade during the course of treatment from
baseline. CONCLUSIONS: Methods used to elicit pref-
erences must be balanced with the practical issues of clin-
ical practice to yield clinically useful options to be used
by clinicians and patients for decision-making. 
EYE & SKIN DISEASES/DISORDERS—Clinical
Outcomes/Healthcare Policy
PES1
FACTORS INFLUENCING A POTENTIALLY
INAPPROPRIATE DERMATOLOGICAL
MEDICATION COMBINATION PRESCRIPTION
AMONG U.S. OUTPATIENT PHYSICIANS
Balkrishnan R, Cook JM, Feldman SR, Fleischer Jr AB
Wake Forest University School of Medicine, Winston-Salem,
NC, USA
OBJECTIVE: Despite concerns associated with the 
necessity of an additional ﬂuorinated, high potency
topical corticosteroid, the clotrimazole/betamethasone
diproprionate combination remains a frequently pre-
scribed topical agent in the U.S. This research was per-
formed to better understand the circumstances in which
physicians across specialties in the U.S. recommend the
use of the combination medication in outpatient settings.
Additionally, the study aimed to determine the diagnoses
and characteristics of patients for whom the combination
medication was prescribed. METHODS: Data from the
National Ambulatory Medical Care Survey (1990-2000)
were used to determine the demographic characteristics
of patients with dermatologic diagnoses who were given
a prescription for clotrimazole/betamethasone dipropri-
onate. The most common diagnoses of patients treated
with the drug were also determined. RESULTS: Family
medicine physicians were more than twice as likely (OR:
2.61, 95% CI: 1.59, 4.30) and internists were more than
3 times as likely (OR: 3.52, 95% CI: 2.07, 5.97) 
to prescribe clotrimazole/betamethasone diproprionate
compared to all other physicians when faced with a der-
matologic diagnosis. Prescription rates of the combina-
tion medication were higher among patients of 
non-white race (OR: 1.55, CI: 1.07, 2.25). Contact 
dermatitis and other eczema ranked highest among 
diagnoses associated with the combination medication
mention by family medicine physicians, internists, and
pediatricians. CONCLUSIONS: The frequent use of
clotrimazole/betamethasone diproprionate by primary
care physicians is of concern. Use of alternative agents
with anti-inﬂammatory and antifungal properties without
the associated risks of high potency topical corticos-
teroids would be a preferable alternative.




BIMATOPROST VERSUS LATANOPROST 
PLUS ADJUNCTIVE PRODUCTS FOR
GLAUCOMA TREATMENT
Walt JH1, Spalding JR2, Habib L3
1Allergan, Irvine, CA, USA; 2University of Southern California,
Los Angeles, CA, USA; 3Keck Graduate Institute, Claremont,
CA, USA
OBJECTIVES: Prostamides have recently been intro-
duced to treat glaucoma patients. We evaluated the effec-
tiveness and pharmacoeconomic impact of these newer
medications in treating patients with glaucoma. We com-
pared effectiveness and costs of bimatoprost monother-
apy versus latanoprost used with adjunctive therapies.
METHODS: A pharmacoeconomic model was con-
structed based on a two-month naturalistic effectiveness
trial comparing bimatoprost 0.03% (AWP of $53.13) in
patients switched from all possible combination therapies
with latanoprost 0.005% (AWP weighted total average
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cost of $78.98). The trial evaluated the percent of patients
achieving target intraocular pressures (IOPs). The cost 
of treatment to achieve the target was calculated as 
medication cost divided by effectiveness based on patients
achieving a target IOP of £17mmHg. This target was
chosen based on the Advanced Glaucoma Intervention
Study (AIGS) which indicated patients whose pressures
were below 18mmHg did not progress over a 6-year
period. The cost-effectiveness calculation was based on
cost and efﬁcacy data during the two-month study period.
RESULTS: With bimatoprost, 59% of patients reached
and maintained a target IOP of £17mm vs. 30% with
latanoprost plus adjunctive medicines (p < 0.05).
Common adjunctive medicines used were beta blockers
(44%), alpha-agonists (27%), CAIs (15%), Cosopt (9%),
and others (5%). The 2-month cost-effectiveness ratio
was $279 vs. $784 per successfully treated patient for
bimatoprost vs. the latanoprost plus adjunctive treat-
ments, respectively. The monthly incremental cost-
effectiveness ratio with brimonidine dominated all 
treatments with latanoprost. CONCLUSIONS: Due to a
greater percentage of glaucoma patients achieving a target
treatment of £17mmHg (considered effectiveness) with
bimatoprost, bimatoprost monotherapy has a more
favorable cost-effectiveness proﬁle than a combination of
latanoprost plus adjunctive treatments.
PES3
A MODEL-BASED PHARMACOECONOMIC
ANALYSIS OF BRIMONIDINE TARTATE 0.2% AS
AN ADJUNCTIVE THERAPY TO BETA-BLOCKERS
IN THE TREATMENT OF GLAUCOMA OR
OCULAR HYPERTENSION IN ADULT PATIENTS
IN NORWAY
Christensen TL1, Poulsen PB1, Holmstrom S2, Maeland K3,
Walt JG4
1MUUSMANN Research & Consulting, Kolding, Denmark;
2Allergan, Mougins, France; 3Allergan, Upplands Vasby, Sweden;
4Allergan, Irvine, CA, USA
OBJECTIVES: Glaucoma is a condition affecting one or
both eyes with raised intraocular pressure (IOP). The IOP
should be reduced to prevent progression of visual ﬁeld
loss. The objective of the present study was to com-
pare the cost-effectiveness of brimonidine tartate 0.2%
(Alphagan) with dorzolamide 2% (Trusopt) as adjunctive
therapies to beta-blockers in the treatment of adult glau-
coma patients in Norway. METHODS: A model based
on effectiveness and resource-use data from an RCT was
constructed. The RCT covered 106 adult patients having
beta-blockers with inadequately controlled IOP. The
major cost-driver was patients who did not reach target
IOP (17mmHg) and needed additional adjunctive thera-
pies. The change to another adjunctive therapy in the
model triggered more expensive medication and extra
follow-up visits at the ophthalmologist. The model
analysed cost-effectiveness from a societal perspective
within a 3-months time horizon. Norwegian unit costs
were included. The measure of effectiveness was “patients
achieving target IOP”. To handle uncertainty sensitivity
analyses (one-way, break-even, extreme scenario) were
undertaken. RESULTS: The RCT showed that 78% of
the patients using brimonidine and 37% using dorzo-
lamide achieved target IOP. The baseline cost-
effectiveness of brimonidine was NOK 1234 per patient
achieving target IOP compared with NOK 2769 for dor-
zolamide (1€ = 7.28 NOK). These results were strength-
ened by the fact that brimonidine was cheaper and more
effective (dominating strategy) for all IOP levels between
13–20mmHg. Even in the worst case brimonidine was
still cost-effective comparing with the best case for dor-
zolamide. The break-even price for brimonidine was
NOK 634 compared with NOK 133 in the baseline analy-
sis. CONCLUSION: Brimonidine was more cost-effective
(dominating) as adjunctive-therapy to beta-blockers than
dorzolamide. Based on this result Norwegian ophthal-
mologists and others should consider brimonidine in
future decision-making regarding choice of adjunctive
therapies in glaucoma treatment.
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COST-EFFECTIVENESS OF BIMATOPROST 0.03%
VERSUS A COMBINATION PRODUCT OF
TIMOLOL 0.5% AND DORZOLAMIDE 2.0% FOR
GLAUCOMA 
Doyle JJ1, Casciano JC1,Walt JG2
1Analytica Group, New York, NY, USA; 2Allergan, Irvine, CA,
USA
OBJECTIVES: To evaluate the cost-effectiveness of
bimatoprost 0.03% versus a combination product of
timolol 0.5% and dorzolamide 2.0% in the treatment 
of glaucoma. METHODS: A pharmacoeconomic model
was constructed based on a 3-month randomized con-
trolled efﬁcacy-trial comparing Lumigan (bimatoprost
0.03%, a prostamide AWP of $53.13) and Cosopt (a
ﬁxed combination product of timolol 0.5% and dorzo-
lamide 2.0% AWP of $43.85). The trial evaluated the
percent of patients achieving target intraocular pressures
(IOPs) throughout the day. The cost of treatment to
achieve target was calculated as medication cost/expected
effectiveness based on patients achieving a target IOP of
<17mmHg. Cost-effectiveness was based on three
months of the trial treatment. RESULTS: With bimato-
prost, 30% of patients reached and maintained a target
IOP of <17mmHg for all measurements throughout the
day vs. 17% with the combination product (p <0.05). At
three-months, cost-effectiveness ratios were $531 vs.
$774 per successful patient for bimatoprost vs. the com-
bination-product. The incremental cost-per additional
treatment success with bimatoprost was $214. CON-
CLUSIONS: Due to a greater percentage of glaucoma
patients achieving ideal target treatment goals (considered
effectiveness) with bimatoprost 0.03%, bimatoprost
monotherapy has a more favorable cost-effectiveness
proﬁle than a combination of timolol 0.5% and dorzo-
lamide 2.0%.
